LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 28

Suchoptionen

  1. Artikel ; Online: Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist.

    He, Handan / Wu, Jinzi J

    Drugs in R&D

    2023  Band 23, Heft 4, Seite(n) 453–464

    Abstract: Background: ASC42 is a non-steroidal farnesoid X receptor agonist currently in clinical development for chronic liver diseases, such as nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) and primary biliary cirrhosis (PBC).: ... ...

    Abstract Background: ASC42 is a non-steroidal farnesoid X receptor agonist currently in clinical development for chronic liver diseases, such as nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) and primary biliary cirrhosis (PBC).
    Objective: The objective of this study was to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ASC42 in healthy subjects.
    Methods: We conducted the first-in-human study of ASC42 following single and multiple ascending doses (SAD/MAD) and food effect in healthy subjects. The SAD study included five cohorts receiving 5-200 mg ASC42 or placebo and one cohort that was given 15 mg ASC42 with a high-fat meal. The MAD study included three cohorts receiving 5-50 mg ASC42 or placebo once-daily (QD) for 14 days.
    Results: A total of 65 healthy subjects were enrolled and one subject in the MAD study (cohort 8, ASC42 50 mg) withdrew from the study due to an unrelated serious adverse event (SAE) of atrial fibrillation. Pruritus was observed at the highest doses (200 mg cohort in SAD and 50 mg cohort in MAD). Most AEs were mild or moderate. No life-threatening or fatal AEs occurred. ASC42 showed a proportional increase in exposure and elimination half-life following both single and multiple dosing. There was a 21% and 37% decrease in area under the curve (AUC) and maximum plasma concentration (C
    Conclusion: ASC42 was well tolerated with a pharmacokinetic profile suitable for QD dosing, and demonstrated dose-dependent targets engagement without altering plasma cholesterol in healthy subjects.
    Trial registration number: NCT04679129.
    Mesh-Begriff(e) Humans ; Dose-Response Relationship, Drug ; Double-Blind Method ; Area Under Curve ; Healthy Volunteers ; Cholesterol
    Chemische Substanzen Cholesterol (97C5T2UQ7J)
    Sprache Englisch
    Erscheinungsdatum 2023-11-02
    Erscheinungsland New Zealand
    Dokumenttyp Journal Article
    ZDB-ID 2020476-0
    ISSN 1179-6901 ; 1174-5886
    ISSN (online) 1179-6901
    ISSN 1174-5886
    DOI 10.1007/s40268-023-00444-4
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5262: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Buch ; Online: Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease

    Wei, Bo / Hang, Xiaofeng / Xie, Ying / Zhang, Yuanjing / Wang, Jianrong / Cao, Xinghao / Wu, Jinzi J. / Wang, Junxue

    Revista da Sociedade Brasileira de Medicina Tropical v.53 2020

    Case reports

    2020  

    Abstract: Abstract Coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic. We herein report four COVID-19 cases with long-term positive viral ribonucleic acid (RNA) for about 61 days. ...

    Abstract Abstract Coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic. We herein report four COVID-19 cases with long-term positive viral ribonucleic acid (RNA) for about 61 days. Despite treatment with recombinant human interferon, convalescent plasma from COVID-19 patients, arbidol, etc., nucleic acid results were still positive for SARS-CoV-2. After treatment with ritonavir-boosted danoprevir (DNVr, 100/100 mg, once daily), all four patients showed two to three consecutive negative SARS-CoV-2 RNA and were thus discharged from hospital. Therefore, DNVr may be a potentially effective antiviral for COVID-19 patients with long-term positive SARS-CoV-2 RNA.
    Schlagwörter COVID-19 ; Antivirals ; Long-term positive SARS-CoV-2 ; covid19
    Sprache Englisch
    Erscheinungsdatum 2020-01-01
    Verlag Sociedade Brasileira de Medicina Tropical - SBMT
    Erscheinungsland br
    Dokumenttyp Buch ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  3. Artikel ; Online: First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients.

    Chen, Hongyi / Zhang, Zhicheng / Wang, Li / Huang, Zhihua / Gong, Fanghua / Li, Xiaodong / Chen, Yahong / Wu, Jinzi J

    Medicine

    2020  Band 99, Heft 48, Seite(n) e23357

    Abstract: Introduction: As coronavirus disease 2019 (COVID-19) outbreak globally, repurposing approved drugs is emerging as important therapeutic options. Danoprevir boosted by ritonavir (Ganovo) is a potent hepatitis C virus (HCV) protease (NS3/4A) inhibitor, ... ...

    Abstract Introduction: As coronavirus disease 2019 (COVID-19) outbreak globally, repurposing approved drugs is emerging as important therapeutic options. Danoprevir boosted by ritonavir (Ganovo) is a potent hepatitis C virus (HCV) protease (NS3/4A) inhibitor, which was approved and marketed in China since 2018 to treat chronic hepatitis C patients.
    Methods: This is an open-label, single arm study evaluating the effects of danoprevir boosted by ritonavir on treatment naïve and experienced COVID-19 patients for the first time. Patients received danoprevir boosted by ritonavir (100 mg/100 mg, twice per day). The primary endpoint was the rate of composite adverse outcomes and efficacy was also evaluated.
    Results: The data showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients. No patient had composite adverse outcomes during this study. After initiation of danoprevir/ritonavir treatment, the first negative reverse real-time PCR (RT-PCR) test occurred at a median of 2 days, ranging from 1 to 8 days, and the obvious absorption in CT scans occurred at a median 3 days, ranging from 2 to 4 days. After 4 to 12-day treatment of danoprevir boosted by ritonavir, all enrolled 11 patients were discharged from the hospital.
    Conclusion: Our findings suggest that repurposing danoprevir for COVID-19 is a promising therapeutic option.
    Mesh-Begriff(e) Adolescent ; Adult ; Aged ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; COVID-19/diagnostic imaging ; COVID-19/drug therapy ; Cyclopropanes/administration & dosage ; Cyclopropanes/adverse effects ; Cyclopropanes/therapeutic use ; Drug Therapy, Combination ; Female ; Humans ; Isoindoles/administration & dosage ; Isoindoles/adverse effects ; Isoindoles/therapeutic use ; Lactams, Macrocyclic/administration & dosage ; Lactams, Macrocyclic/adverse effects ; Lactams, Macrocyclic/therapeutic use ; Male ; Middle Aged ; Pandemics ; Proline/administration & dosage ; Proline/adverse effects ; Proline/analogs & derivatives ; Proline/therapeutic use ; Real-Time Polymerase Chain Reaction ; Ritonavir/administration & dosage ; Ritonavir/adverse effects ; Ritonavir/therapeutic use ; SARS-CoV-2 ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Sulfonamides/therapeutic use ; Tomography, X-Ray Computed ; Young Adult
    Chemische Substanzen Antiviral Agents ; Cyclopropanes ; Isoindoles ; Lactams, Macrocyclic ; Sulfonamides ; danoprevir (911Z9PCQ5F) ; Proline (9DLQ4CIU6V) ; Ritonavir (O3J8G9O825)
    Sprache Englisch
    Erscheinungsdatum 2020-11-20
    Erscheinungsland United States
    Dokumenttyp Clinical Trial ; Journal Article
    ZDB-ID 80184-7
    ISSN 1536-5964 ; 0025-7974
    ISSN (online) 1536-5964
    ISSN 0025-7974
    DOI 10.1097/MD.0000000000023357
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ua VI Zs.171: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports.

    Wei, Bo / Hang, Xiaofeng / Xie, Ying / Zhang, Yuanjing / Wang, Jianrong / Cao, Xinghao / Wu, Jinzi J / Wang, Junxue

    Revista da Sociedade Brasileira de Medicina Tropical

    2020  Band 53, Seite(n) e20200372

    Abstract: Coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic. We herein report four COVID-19 cases with long-term positive viral ribonucleic acid (RNA) for about 61 days. Despite ...

    Abstract Coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic. We herein report four COVID-19 cases with long-term positive viral ribonucleic acid (RNA) for about 61 days. Despite treatment with recombinant human interferon, convalescent plasma from COVID-19 patients, arbidol, etc., nucleic acid results were still positive for SARS-CoV-2. After treatment with ritonavir-boosted danoprevir (DNVr, 100/100 mg, once daily), all four patients showed two to three consecutive negative SARS-CoV-2 RNA and were thus discharged from hospital. Therefore, DNVr may be a potentially effective antiviral for COVID-19 patients with long-term positive SARS-CoV-2 RNA.
    Mesh-Begriff(e) Adult ; Aged ; Antiviral Agents/therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Humans ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; RNA, Viral/blood ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemische Substanzen Antiviral Agents ; RNA, Viral
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-07-20
    Erscheinungsland Brazil
    Dokumenttyp Case Reports ; Journal Article
    ZDB-ID 1038126-0
    ISSN 1678-9849 ; 0037-8682
    ISSN (online) 1678-9849
    ISSN 0037-8682
    DOI 10.1590/0037-8682-0372-2020
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2726: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel: Comparison of SPA, FRET, and FP for kinase assays.

    Wu, Jinzi J

    Methods in molecular biology (Clifton, N.J.)

    2002  Band 190, Seite(n) 65–85

    Mesh-Begriff(e) Amino Acid Sequence ; Animals ; Antibodies ; Drug Design ; Drug Evaluation, Preclinical ; Fluorescence Polarization/methods ; Fluorescence Resonance Energy Transfer/methods ; Humans ; Molecular Biology/methods ; Oligopeptides/chemistry ; Protein Kinase C/analysis ; Protein Kinases/analysis ; Protein Kinases/immunology ; Protein-Serine-Threonine Kinases/analysis ; Protein-Tyrosine Kinases/analysis ; Scintillation Counting ; Substrate Specificity
    Chemische Substanzen Antibodies ; Oligopeptides ; Protein Kinases (EC 2.7.-) ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; Protein-Serine-Threonine Kinases (EC 2.7.11.1) ; Protein Kinase C (EC 2.7.11.13)
    Sprache Englisch
    Erscheinungsdatum 2002
    Erscheinungsland United States
    Dokumenttyp Comparative Study ; Journal Article
    ISSN 1064-3745
    ISSN 1064-3745
    DOI 10.1385/1-59259-180-9:065
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  6. Artikel ; Online: Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.

    Kao, Jia-Horng / Yu, Min-Lung / Chen, Chi-Yi / Peng, Cheng-Yuan / Chen, Ming-Yao / Tang, Huoling / Chen, Qiaoqiao / Wu, Jinzi J

    Journal of gastroenterology and hepatology

    2018  Band 33, Heft 8, Seite(n) 1507–1510

    Abstract: Background and aim: The need for all-oral hepatitis C virus (HCV) treatments with higher response rates, improved tolerability, and lower pill burden compared with interferon-inclusive regimen has led to the development of new direct-acting antiviral ... ...

    Abstract Background and aim: The need for all-oral hepatitis C virus (HCV) treatments with higher response rates, improved tolerability, and lower pill burden compared with interferon-inclusive regimen has led to the development of new direct-acting antiviral agents. Ravidasvir (RDV) is a second-generation, pan-genotypic NS5A inhibitor with high barrier to resistance. The aim of this phase 2 study (EVEREST study) was to assess the efficacy and safety of interferon-free, 12-week RDV plus ritonavir-boosted danoprevir (DNVr) and ribavirin (RBV) regimen for treatment-naïve Asian HCV genotype 1 (GT1) patients without cirrhosis.
    Methods: A total of 38 treatment-naïve, non-cirrhotic adult HCV GT1 patients were enrolled in this multicenter, open-label, single-arm phase 2 study (NCT03020095). All patients received a combination of RDV 200 mg once daily (q.d.) plus DNVr 100 mg/100 mg twice daily (b.i.d.) and oral RBV 1000/1200 mg/day (body weight < 75/≥ 75 kg) for 12 weeks. The primary endpoint was the rate of sustained virologic response 12 weeks after the end of treatment (SVR12).
    Results: Of 38 patients, all (100%) achieved SVR12. During the study, no treatment-related serious adverse events, no patients discontinued treatment due to adverse events, and no deaths were reported. Six of 37 (16%) patients with available sequences had HCV NS5A resistance-associated variants at baseline. All patients (6/6) with baseline NS5A resistance-associated variants achieved SVR12.
    Conclusions: Twelve-week RDV and DNVr in combination with RBV for 12 weeks achieves the SVR12 rate of 100% in treatment-naïve non-cirrhotic Asian patients with HCV GT1 infection. This interferon-free regimen is also safe and well tolerated.
    Mesh-Begriff(e) Administration, Ophthalmic ; Adult ; Aged ; Aged, 80 and over ; Antiviral Agents ; Asian Continental Ancestry Group ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Genotype ; Hepacivirus/genetics ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/virology ; Humans ; Lactams/administration & dosage ; Liver Cirrhosis ; Male ; Middle Aged ; Ribavirin/administration & dosage ; Ritonavir/administration & dosage ; Sulfonamides/administration & dosage ; Time Factors ; Treatment Outcome
    Chemische Substanzen Antiviral Agents ; Lactams ; Sulfonamides ; Ribavirin (49717AWG6K) ; danoprevir (911Z9PCQ5F) ; Ritonavir (O3J8G9O825)
    Sprache Englisch
    Erscheinungsdatum 2018-03-12
    Erscheinungsland Australia
    Dokumenttyp Clinical Trial, Phase II ; Journal Article ; Multicenter Study
    ZDB-ID 632882-9
    ISSN 1440-1746 ; 0815-9319
    ISSN (online) 1440-1746
    ISSN 0815-9319
    DOI 10.1111/jgh.14096
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2180: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 299: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel: Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports

    Wei, Bo / Hang, Xiaofeng / Xie, Ying / Zhang, Yuanjing / Wang, Jianrong / Cao, Xinghao / Wu, Jinzi J. / Wang, Junxue

    Revista da Sociedade Brasileira de Medicina Tropical

    Abstract: Coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic We herein report four COVID-19 cases with long-term positive viral ribonucleic acid (RNA) for about 61 days Despite ... ...

    Abstract Coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic We herein report four COVID-19 cases with long-term positive viral ribonucleic acid (RNA) for about 61 days Despite treatment with recombinant human interferon, convalescent plasma from COVID-19 patients, arbidol, etc , nucleic acid results were still positive for SARS-CoV-2 After treatment with ritonavir-boosted danoprevir (DNVr, 100/100 mg, once daily), all four patients showed two to three consecutive negative SARS-CoV-2 RNA and were thus discharged from hospital Therefore, DNVr may be a potentially effective antiviral for COVID-19 patients with long-term positive SARS-CoV-2 RNA
    Schlagwörter covid19
    Verlag WHO
    Dokumenttyp Artikel
    Anmerkung WHO #Covidence: #665936
    Datenquelle COVID19

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  8. Artikel ; Online: First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients

    Chen, Hongyi / Zhang, Zhicheng / Wang, Li / Huang, Zhihua / Gong, Fanghua / Li, Xiaodong / Chen, Yahong / WU, Jinzi J.

    Abstract: As coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), started in China in January, 2020, repurposing approved drugs is emerging as important therapeutic options. We reported here the ... ...

    Abstract As coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), started in China in January, 2020, repurposing approved drugs is emerging as important therapeutic options. We reported here the first clinical study using hepatitis C virus (HCV) protease inhibitor, danoprevir, to treat COVID-19 patients. Danoprevir (Ganovo) is a potent HCV protease (NS3/4A) inhibitor (IC50 = 0.29 nM), which was approved and marketed in China since 2018 to treat chronic hepatitis C patients. Ritonavir is a CYP3A4 inhibitor to enhance plasma concentration of danoprevir while it also acts as a human immunodeficiency virus (HIV) protease inhibitor at high doses. The chymotrypsin-like protease of SARS-CoV-2 shares structure similarity with HCV and HIV proteases. In the current clinical study (NCT04291729) conducted at the Nineth Hospital of Nanchang, we evaluated therapeutic effects of danoprevir, boosted by ritonavir, on treatment naive and experienced COVID-19 patients. The data from this small-sample clinical study showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients. After 4 to 12-day treatment of danoprevir boosted by ritonavir, all eleven patients enrolled, two naive and nine experienced, were discharged from the hospital as they met all four conditions as follows: (1) normal body temperature for at least 3 days; (2) significantly improved respiratory symptoms; (3) lung imaging shows obvious absorption and recovery of acute exudative lesion; and (4) two consecutive RT-PCR negative tests of SARS-CoV-2 nucleotide acid (respiratory track sampling with interval at least one day). Our findings suggest that repurposing danoprevir for COVID-19 is a promising therapeutic option.
    Schlagwörter covid19
    Verlag MedRxiv; WHO
    Dokumenttyp Artikel ; Online
    DOI 10.1101/2020.03.22.20034041
    Datenquelle COVID19

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  9. Artikel ; Online: First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients

    Chen, Hongyi / Zhang, Zhicheng / Wang, Li / Huang, Zhihua / Gong, Fanghua / Li, Xiaodong / Chen, Yahong / WU, Jinzi J.

    medRxiv

    Abstract: As coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), started in China in January, 2020, repurposing approved drugs is emerging as important therapeutic options. We reported here the ... ...

    Abstract As coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), started in China in January, 2020, repurposing approved drugs is emerging as important therapeutic options. We reported here the first clinical study using hepatitis C virus (HCV) protease inhibitor, danoprevir, to treat COVID-19 patients. Danoprevir (Ganovo) is a potent HCV protease (NS3/4A) inhibitor (IC50 = 0.29 nM), which was approved and marketed in China since 2018 to treat chronic hepatitis C patients. Ritonavir is a CYP3A4 inhibitor to enhance plasma concentration of danoprevir while it also acts as a human immunodeficiency virus (HIV) protease inhibitor at high doses. The chymotrypsin-like protease of SARS-CoV-2 shares structure similarity with HCV and HIV proteases. In the current clinical study (NCT04291729) conducted at the Nineth Hospital of Nanchang, we evaluated therapeutic effects of danoprevir, boosted by ritonavir, on treatment naive and experienced COVID-19 patients. The data from this small-sample clinical study showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients. After 4 to 12-day treatment of danoprevir boosted by ritonavir, all eleven patients enrolled, two naive and nine experienced, were discharged from the hospital as they met all four conditions as follows: (1) normal body temperature for at least 3 days; (2) significantly improved respiratory symptoms; (3) lung imaging shows obvious absorption and recovery of acute exudative lesion; and (4) two consecutive RT-PCR negative tests of SARS-CoV-2 nucleotide acid (respiratory track sampling with interval at least one day). Our findings suggest that repurposing danoprevir for COVID-19 is a promising therapeutic option.
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-03-24
    Verlag Cold Spring Harbor Laboratory Press
    Dokumenttyp Artikel ; Online
    DOI 10.1101/2020.03.22.20034041
    Datenquelle COVID19

    Volltext online

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  10. Artikel ; Online: Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy.

    Chen, Yunching / Wu, Jinzi J / Huang, Leaf

    Molecular therapy : the journal of the American Society of Gene Therapy

    2010  Band 18, Heft 4, Seite(n) 828–834

    Abstract: We have designed a PEGylated LPD (liposome-polycation-DNA) nanoparticle for systemic, specific, and efficient delivery of small interfering RNA (siRNA) into solid tumors in mice by modification with NGR (aspargine-glycine-arginine) peptide, targeting ... ...

    Abstract We have designed a PEGylated LPD (liposome-polycation-DNA) nanoparticle for systemic, specific, and efficient delivery of small interfering RNA (siRNA) into solid tumors in mice by modification with NGR (aspargine-glycine-arginine) peptide, targeting aminopeptidase N (CD13) expressed in the tumor cells or tumor vascular endothelium. LPD-PEG-NGR efficiently delivered siRNA to the cytoplasm and downregulated the target gene in the HT-1080 cells but not CD13(-) HT-29 cells, whereas nanoparticles containing a control peptide, LPD-PEG-ARA, showed only little siRNA uptake and gene silencing activity. LPD-PEG-NGR efficiently delivered siRNA into the cytoplasm of HT-1080 xenograft tumor 4 hours after intravenous injection. Three daily injections (1.2 mg/kg) of c-myc siRNA formulated in the LPD-PEG-NGR effectively suppressed c-myc expression and triggered cellular apoptosis in the tumor, resulting in a partial tumor growth inhibition. When doxorubicin (DOX) and siRNA were co-formulated in LPD-PEG-NGR, an enhanced therapeutic effect was observed.
    Mesh-Begriff(e) Animals ; Antibiotics, Antineoplastic/administration & dosage ; Apoptosis ; CD13 Antigens/pharmacology ; Cell Line, Tumor ; Doxorubicin/administration & dosage ; Drug Delivery Systems ; Endothelium, Vascular ; Genes, myc ; HT29 Cells ; Humans ; Liposomes ; Mice ; Mice, Nude ; Nanoparticles/administration & dosage ; Neoplasms/drug therapy ; Oligopeptides/administration & dosage ; RNA, Small Interfering/administration & dosage ; Xenograft Model Antitumor Assays
    Chemische Substanzen Antibiotics, Antineoplastic ; Liposomes ; NGR peptide ; Oligopeptides ; RNA, Small Interfering ; Doxorubicin (80168379AG) ; CD13 Antigens (EC 3.4.11.2)
    Sprache Englisch
    Erscheinungsdatum 2010-01-12
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2010592-7
    ISSN 1525-0024 ; 1525-0016
    ISSN (online) 1525-0024
    ISSN 1525-0016
    DOI 10.1038/mt.2009.291
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5640: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang